Kharbanda Rohit K, Moore Jeremy P, Taverne Yannick J H J, Bramer Wichor M, Bogers Ad J J C, de Groot Natasja M S
Department of Cardiology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands; Department of Cardiothoracic Surgery, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.
Ahmanson/UCLA Adult Congenital Heart Disease Center, Los Angeles, California, United States of America.
Int J Cardiol. 2020 Nov 1;318:74-81. doi: 10.1016/j.ijcard.2020.06.052. Epub 2020 Jul 6.
Patients with a systemic right ventricle (SRV) are at high risk for development of heart failure early in life. An SRV is encountered in patients with congenitally corrected transposition of the great arteries (CCTGA) or dextro-transposition of the great arteries (DTGA) with previous atrial switch repair (Mustard or Senning procedure). Progressive heart failure is one of the leading cause of mortality in these patients. Therefore, cardiac resynchronization therapy (CRT) has gained increasing momentum for use in this challenging congenital heart disease (CHD) population. However, current guidelines differ in recommendations for CRT in patients with an SRV as evidence supporting CRT has thus far only been described in case reports and retrospectively in relatively small study populations. In fact, the European Society of Cardiology Guideline for the management of grown-up congenital heart disease consider CRT to be 'experimental' in this population. This systematic review critically summarizes current literature on CRT in SRV patients and provides future perspectives for further research in this challenging and growing CHD population.
患有系统性右心室(SRV)的患者在生命早期发生心力衰竭的风险很高。在患有大动脉转位矫正型先天性心脏病(CCTGA)或大动脉右位转位(DTGA)且先前接受过心房调转修复术(Mustard或Senning手术)的患者中会出现SRV。进行性心力衰竭是这些患者死亡的主要原因之一。因此,心脏再同步治疗(CRT)在这一具有挑战性的先天性心脏病(CHD)人群中的应用越来越受到关注。然而,目前的指南对于SRV患者CRT的推荐存在差异,因为迄今为止支持CRT的证据仅在病例报告中有所描述,且在相对较小的研究人群中为回顾性研究。事实上,欧洲心脏病学会成人先天性心脏病管理指南认为CRT在这一人群中是“试验性的”。本系统综述批判性地总结了目前关于SRV患者CRT的文献,并为这一具有挑战性且不断增长的CHD人群的进一步研究提供了未来展望。